PAR-25-322: Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)

Captured cycle: This page is retained for historical guidance. Confirm whether the program has reopened before planning an application.

PAR-25-322: Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)

Executive summary

PAR-25-322 is a National Institutes of Health (NIH) parent R01 mechanism tailored specifically for Early Stage Investigators who want to pivot into a new research direction where they have no preliminary data yet. The opportunity is unusual among NIH R01-style funding because it explicitly requires a directional shift: your proposed project must be anchored in a changed trajectory and cannot be an incremental extension of prior work. It is also explicit that preliminary data are not allowed in the application, which makes this NOFO materially different from standard NIH project grants.

In 2026 and 2027, this NOFO is one of the most practical “high signal” options for early investigators planning bold, high-risk, early-stage work that would otherwise be difficult to justify under conventional R01 announcements. It is not a one-off “single day” cycle: NIH publishes recurring due dates and review rounds, so there are multiple opportunities across both years if your team becomes submission-ready in time.

The NOFO is open to U.S. organizations only and does not accept foreign organizations as primary applicants. It prohibits clinical trial proposals, while still permitting work involving human subjects or animals when properly justified and compliant with NIH instructions.

At-a-glance details

What this opportunity actually is

This is often misunderstood as a standard independent PI path because it uses the R01 mechanism and supports full research scope through substantial NIH review. In practice it is much more specific: it is a “new-direction” instrument for qualified ESIs. The official NOFO language states that projects must not include preliminary data and must clearly represent a change in direction from the applicant’s existing research history.

This changes how you should think about proposal design:

• Your hypothesis can be more exploratory and conceptually risky than usual.
• Your proof plan must lean on logic, expertise, literature grounding, and public data rather than unpublished pilot results.
• The narrative should be built around feasibility despite limited direct preliminary evidence.

The intent is to open room for high-risk conceptual transitions that may not yet have generated robust pilot outputs but still have enough plausibility and scientific urgency to warrant an NIH R01-scale investment.

That design objective creates tension in many proposals:

• If your proposal reads like a conservative continuation, reviewers and program staff may classify it as not aligned with the mechanism.
• If your proposal has no explicit feasibility strategy, it will struggle against more rigorous applications under the same cycle.
• If your application appears underprepared on feasibility just because preliminary data are absent, it may fail compliance expectations around rigor and rationale.

In short: do not treat this as “just another R01.” Treat it as a policy-shaped portfolio slot for credible directional changes.

Who this is for (and who should skip it)

Strongly aligned applicants

1. ESIs with a clear pivot. You are strongest when you can show your prior training and output were in a related area, but the new direction differs enough to constitute a new conceptual trajectory.

2. Candidates with domain transfer. People moving from one field into another closely adjacent domain—where they can import transferable reasoning but not duplicate prior data streams—typically fit best.

3. Applicants with an institution that can show strong mentorship for pivot transitions. Even though this is still an independent award, PD/PI support from a strong scientific environment matters substantially because data absence means reviewers want to see structure, feasibility, and execution capability.

Applicants who usually do not fit

1. Teams proposing clinical trials. This mechanism explicitly excludes clinical trials.

2. Labs seeking to recycle existing project lines. This is not the right place for incremental continuation.

3. Applicants with a multi-year, fully prepared pilot data package that already exists but is only now being formalized in prose. If preliminary data are central to the science story, another NOFO may be more appropriate.

4. Non-U.S. organizations (as primary applicant). Non-domestic entities are not eligible to apply as applicants; foreign components of U.S. entities are also not eligible, so institutional structure matters.

Eligibility and hard compliance filters

The NOFO has several gating rules that are not “nice-to-have” and will remove your application quickly if missed.

ESI requirement

All PD/PI(s) must be Early Stage Investigators as defined by NIH guidance. For multiple PIs, every PD/PI must individually meet this criterion and the proposed project must represent a direction change for each of them. This is a strict point in the rules set: mixed seniority or mixed-stage teams are not aligned with this mechanism without correction.

No preliminary data rule

The official announcement is explicit that applications must not include preliminary data. That includes data that are not yet published and not publicly available. Proposals that violate this are noncompliant. If you include references, those should be from published/preprint sources and explicitly cited according to NIH instructions.

New-research-direction documentation

The mechanism requires a dedicated attachment in SF424(R&R) Other Project Information titled “New Research Direction,” describing why this proposed project is a directional shift relative to prior work. The NOFO includes a one-page limit for this attachment, and this limit applies per PD/PI in MPI applications. Missing this attachment or exceeding allowed length is treated as a compliance failure.

Organization eligibility

Eligible organizations include U.S. higher education institutions, nonprofits (both 501(c)(3) and non-501(c)(3) in many forms), small and larger for-profits, local government entities, certain federal agencies, and additional U.S.-based structures listed in the NOFO. The key point: non-domestic entities are not eligible as applicants.

Registration and identity requirements

NIH is explicit that applications are not accepted if required registrations are incomplete. These must be ready before submission:

• SAM and UEI registration (with CAGE/NCAGE workflow as needed)
• eRA Commons
• Grants.gov registration
• Valid institutional profile and designated signing official / PD-PI mapping

The NOFO clarifies that registration delays can take six weeks or more. In practice this means teams should begin by the start of cycle planning, not near submission.

Application windows, timeline, and planning strategy (2026/2027)

PAR-25-322 is run through recurring cycles. The Key Dates table includes overlapping submission and review windows that continue through 2028. For planning in 2026/2027, the NOFO’s recurring schedule includes (partial example):

• 2026-01-27 (new submission window)
• 2026-05-27
• 2026-09-28
• 2027-01-26
• 2027-05-28
• 2027-09-28

Each submission date corresponds to specific review and award timing, and all are tied to local 5:00 PM due-time.

Important planning implications:

1. You can choose a later cycle if your PI portfolio or institutional signatures are not ready.
2. Missing one due date does not mean the program is over.
3. Your preparation quality should rise, not slide, across cycles. A cycle skipped for readiness is often lower-cost than a rushed noncompliant submission.

A good planning approach is to maintain a twelve-week prep cycle from first draft to final checks:

• Weeks 12-10: Confirm ESI fit and IC interest.
• Weeks 10-8: Draft change-of-direction attachment and full scientific plan.
• Weeks 8-6: Align methods and feasibility narrative to the lack of preliminary data.
• Weeks 6-4: Complete internal compliance checks and page-limit pass.
• Weeks 4-2: Run human subjects/animal sections and policy forms.
• Weeks 2-0: Pre-submission validation via ASSIST/Grants.gov and sponsor sign-off.

Submission flow and content requirements that matter most

The NOFO allows three submission paths: NIH ASSIST, institutional S2S to Grants.gov/eRA, or Grants.gov Workspace. The mechanism itself is not forgiving on format mistakes, and the compliance language is strict.

Required structure in practice

Your package should be built around three linked components:

1. Research Strategy Explicitly prove feasibility under no-preliminary-data constraints. Reviewers need to see why your approach can work, not just what you want to do.

2. Rigor in references and literature If any data are included, they must be published with valid DOIs for preprints and publications where applicable; data without DOI are disallowed in relevant sections.

3. New-research-direction attachment This is not decorative. It is the mechanism’s gate statement and should not be generic. It should explain:

   • what changed,
   • why change is strategic,
   • why prior training still supports successful execution,
   • what risk exists and how you will manage it.

Common compliance gotchas

• Missing or incomplete registrations.
• Duplicate applications with overlap under active review.
• Multiple MPI proposals where not all PD/PIs are ESIs.
• Exceeding attachment page limits.
• Submitting preliminary data despite the explicit prohibition.
• Treating this as a standard R01 with no emphasis on directional change.

The NOFO also requires a Data Management and Sharing Plan when applicable and standard NIH forms for human subjects, animal use, biohazards, and other ethics and reporting requirements where relevant.

Review and funding logic

NIH evaluates this through standard scientific review with criteria adapted to the mechanism’s intent. It is not a formality process; reviewer expectations remain high and the NOFO includes a high bar for innovation and significance framing.

The review discussion is likely to focus on:

• Clarity that the project reflects a genuine new direction.
• How strong and coherent the concept is without preliminary data.
• Feasibility of execution within planned budget and time.
• Institutional and PI readiness, especially in the absence of preliminary data.

After review, funding decisions remain constrained by the usual NIH factors: peer-review quality, appropriations, and programmatic fit. The NOFO does not advertise a fixed number of awards; awards depend on available funds and the quality of applications.

Preparation and execution checklist for 2026/2027 applicants

Before submission

• Confirm each PD/PI is validly classified as an ESI.
• Decide whether publication history and current expertise can support the pivot.
• Draft a one-page change-of-direction memo before writing the full scientific strategy.
• Confirm all registrations are active and linked through the proper org profile.
• Verify all required NIH system accounts and role assignments.

During writing

• Front-load novelty and conceptual break in the strategy sections.
• Emphasize why the question could not be reasonably addressed under your prior track.
• Replace pilot-data assumptions with literature, public resources, or clear inferential logic.
• Add milestones and measurable outputs mapped to risk reduction.

In final 72 hours

• Run a strict page-limit pass against NIH instructions and NOFO add-ons.
• Confirm human/animal bio sections are complete and aligned.
• Validate DOI handling for any references with data.
• Check the 5:00 PM local due-time and ensure institutional review and signing workflow close before that buffer.

After submission

• Monitor eRA Commons for review assignment.
• Expect summary statements and potentially just-in-time requests where relevant.
• Keep compliance documentation for SAM/financial systems because post-award review includes responsibility and qualification checks.

Frequently asked questions

Is this a standard NIH R01?

It uses R01 structure and review context, but with explicit restrictions and a change-of-direction design requirement. Treating it as a standard R01 can weaken your fit.

Can I include preliminary data if it supports feasibility?

No. The NOFO states applications must not include preliminary data for this mechanism.

Is this recurring or does it expire quickly?

The NOFO is open to multiple rounds in 2026/2027 and beyond, with recurring due dates through August 2028. That does not remove deadlines; it gives repeated cycles.

Can foreign institutions apply as prime?

No. Non-domestic (non-U.S.) entities are not eligible as applicant organizations. Even foreign components of U.S. organizations are not allowed in this context.

Can two senior investigators file together?

Multiple PD/PIs are allowed only if every PD/PI is an ESI and the direction change is true for each applicant.

What is the funding amount?

The NOFO page does not provide a fixed “award ceiling” like a standard challenge grant. It states budgets are not limited to a strict cap, and project budgets should be tied to actual need.

Common mistakes and reviewer penalties

• Submission as if preliminary data were allowed: often a major compliance rejection.
• Weak “new direction” narrative: if this reads as incremental, application risks being judged misaligned at intake or review.
• No evidence of environment readiness: since this is pivoting work, reviewer confidence depends on sponsor and institutional support.
• Registration failures: incomplete SAM/eRA/Grants.gov setup is a recurring reason for late, invalid, or rejected submission.
• Assuming recurring cycles means last minute: each cycle still needs full preparation and forms compliance.

Why this can be powerful for the right applicant

For the right profile, PAR-25-322 can be unusually strong because it reduces two common friction points:

1. you do not need preliminary data that many PI-level projects depend on for first-cycle competitiveness, and 2) it gives a formal route to pursue a strategic field shift when your skills and environment justify the jump.

The opportunity is best used when the applicant can justify:

• a coherent reason for pivot,
• a realistic methodology that can be launched without relying on pilot data,
• and an institution that can absorb the transition risk.

When those three are present, this mechanism is often reviewed as a true innovation play rather than a compliance edge case.

Official links and contacts

• Official NOFO: https://grants.nih.gov/grants/guide/pa-files/PAR-25-322.html
• NIH E-mail help for general grant process: [email protected]
• Grants.gov support: [email protected]
• eRA/ASSIST help portal: https://www.era.nih.gov/need-help
• Companion mechanism for clinical-trial-eligible line: PAR-25-323 (R01, with clinical trial allowed)

Final recommendation

If your team is an ESI-led group with a genuinely new project angle and no preliminary data requirement, and if your timeline can accommodate NIH-style registrations and compliance from day one, this is one of the strongest NIH opportunities for 2026/2027. If your project has existing preliminary data and a strong incremental pathway, choose a different NOFO instead and avoid fit risk.